Intrexon | XON - Cash And Equivalent


Intrexon reported $9.34M in Cash and Equivalent for its fiscal quarter ending in June of 2024.





Cash And Equivalent Change Date
Agenus USD 35M 32M Mar/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
Anika Therapeutics USD 41.02M 16.46M Mar/2026
Arrowhead Research USD 201.64M 112.94M Dec/2025
AstraZeneca USD 7.56B 1.85B Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Gilead Sciences USD 7.56B 234M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Heron Therapeutics USD 26.12M 2.53M Mar/2026
Incyte USD 4.02B 435.22M Mar/2026
Intrexon USD 9.34M 1.77M Jun/2024
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
Ligand Pharmaceuticals USD 115.08M 59.85M Mar/2026
MacroGenics USD 66.52M 9.3M Mar/2026
MannKind USD 52.83M 22.05M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Veracyte USD 263.14M 99.44M Mar/2026
Xencor USD 14.17M 39.9M Mar/2026